Fabrizio Giuliani
Contact
Associate Professor, Faculty of Medicine & Dentistry - Medicine Dept
- giuliani@ualberta.ca
Overview
Area of Study / Keywords
Multiple Sclerosis MS
About
Personal Statement:
About 14,000 Albertans have multiple sclerosis (MS), one of the highest rates in Canada. This neurological autoimmune disease predominantly affects young people, is unpredictable in its progress, and can have debilitating physical symptoms. In addition to my clinical work, I am involved in basic research and clinical trials aimed at finding potential targets for treatments to slow or halt the progression of MS.
Dr. Fabrizio Giuliani completed his medical degree and residency in adult neurology in Italy. While a resident, he did specialized training at the University of London and the Max-Plank Institute for Neurobiology in Germany. He came to Alberta, funded by the former Alberta Heritage Foundation for Medical Research, to do research training at the University of Calgary and was subsequently recruited to the University of Alberta in 2005.
Leadership and Collaborations:
Dr. Giuliani leads the Multiple Sclerosis Experimental Therapeutics Program at the University of Alberta. The program’s intent is to translate research more effectively into better diagnosis and care for patients. He is a member of the Alberta MS Research Collaboration and the Peter S. Allen MS Research Centre. He is co-investigator for most clinical trials and implemented a clinical database (EDMUS) of more than 1000 patients in the MS Clinic.
Clinical Interests
Dr. Giuliani is an attending physician at the University Hospital and medical director of the multidisciplinary Northern Alberta Multiple Sclerosis Clinic in the Kaye Edmonton Clinic.
Research
Dr. Giuliani’s research focuses on mechanisms of neurodegenerative processes of multiple sclerosis and the development of new therapeutic strategies to prevent neuronal injury in inflammatory diseases of the central nervous system. He is part of the research team that in 2017 discovered a key brain protein that catalyzes cell death and inflammation causing progressive disability in MS patients over time. He has published more than 100 abstracts, reviews and scientific articles in peer-reviewed journals such as Lancet Neurology, Neurology, The Journal of Neuroinflammation, Neuroimmunology and Neuroinflammation and the Journal of Immunology.
Dr. Giuliani’s research has been funded by several agencies including the University Hospital Foundation, Canadian Institutes of Health Research, former Alberta Heritage Foundation for Medical Research, the Multiple Sclerosis Society of Canada (Donald Paty Career Award), as well as such industry partners as Biogen Idec Canada and Roche.
Dr. Giuliani is a scientific grant reviewer for the Canadian Institutes of Health Research, the Multiple Sclerosis Society of Canada and for the University of Alberta’s Killam Fellowships. He is a contributing editor at several scientific journals including the MS Journal, the Journal of Neuroimmunology and the Canadian Journal of Neurological Sciences.
Teaching
Dr. Giuliani is a classroom instructor in neuroscience and a small group instructor for medical students. He also delivers bedside teaching sessions for residents and clinical skills for medical students.
Featured Publications
Samira Samtleben, Lucas Mina, Megan C. Yap, William G. Branton, Muhammad Saad Yousuf, Gustavo Tenorio, Klaus Ballanyi, Fabrizio Giuliani, Bradley J. Kerr, Christopher Power, and Thomas Simmen
EUROPEAN JOURNAL OF NEUROSCIENCE. 2022 July; N/A
Bibin Anand, Qi Wu, Maryam Nakhaei-Nejad, Govindarajan Karthivashan,Lyudmyla Dorosh, Sara Amidian, Abhishek Dahal, Xiuju Li, Maria Stepanova, Holger Wille, Fabrizio Giuliani, Satyabrata Kara
Bioactive Materials. 2022 May; 17 https://doi.org/10.1016/j.bioactmat.2022.05.030
Galleguillos D., Wang Q., Steinberg N., Zaidi A., Shrivastava G., Dhami K., Daskhan G.C., Schmidt E.N., Dworsky-Fried Z., Giuliani F., Churchward M., Power C., Todd K., Taylor A., Macauley M.S., Sipione S.
Journal of Neuroinflammation. 2022 January; 19 (1) 10.1186/s12974-021-02374-x
Oh J., Arbour N., Giuliani F., Guenette M., Kolind S., Lynd L., Marrie R.A., Metz L.M., Patten S.B., Prat A., Schabas A., Smyth P., Tam R., Traboulsee A., Yong V.W.
BMC Neurology. 2021 October; 21 (1) 10.1186/s12883-021-02447-7
Chen J., Bassot A., Giuliani F., Simmen T.
Cells. 2021 July; 10 (7) 10.3390/cells10071789
Lee C.H., Jiang B., Nakhaei-Nejad M., Barilla D., Blevins G., Giuliani F.
Multiple Sclerosis and Related Disorders. 2021 July; 52 10.1016/j.msard.2021.103003
Alluqmani M., Roda W., Qqrmli M., Blevins G., Giuliani F., Power C.
BMC Neurology. 2021 July; 21 (1) 10.1186/s12883-021-02317-2
Camara-Lemarroy C.R., Silva C., Metz L.M., Cerchiaro G., Greenfield J., Dowlatabadi R., Vogel H.J., Lee C.H., Giuliani F., Nakhaei-Nejad M., Li D.K.B., Traboulsee A., Yong V.W.
Multiple Sclerosis and Related Disorders. 2021 May; 50 10.1016/j.msard.2021.102809
Cheng C., Gomez D., McCombe J.A., Smyth P., Giuliani F., Blevins G., Baker G.B., Power C.
Neurological Sciences. 2021 January; 10.1007/s10072-021-05203-4